AbbVie Inc., et al.

Last Updated:
Federal Trade Commission, Plaintiff, v. AbbVie Inc.; Abbott Laboratories; Unimed Pharmaceuticals, LLC; Besins Healthcare, Inc.; and Teva Pharmaceuticals USA, Inc., Defendants
FTC Matter/File Number:

121 0028

Enforcement Type:

Federal Injunctions

Federal Court:
Eastern District of Pennsylvania

Case Summary

The FTC filed a complaint in federal district court in September 2014 charging that AbbVie Inc. and its partner Besins Healthcare Inc. illegally blocking American consumers’ access to lower-cost alternatives to Androgel by filing baseless patent infringement lawsuits against potential generic competitors. In a June 2018 decision, the U.S. District Court for the Eastern District of Pennsylvania ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone replacement drug Androgel, and ordered $448 million in monetary relief to consumers who were overcharged for Androgel as a result of AbbVie’s conduct. This court order represents the largest monetary award ever in a litigated FTC antitrust case.